Inventor
GRAY NANCY M
US30 patents
⚠️ This page may combine multiple inventors who share the name “GRAY NANCY M”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
SEPRACOR INC
19 patentsUS5985868ANov 16, 1999
Methods and compositions for treating androgen-dependant diseases using optically pure R-(-) casodex
SEPRACOR INC68 citations96
US5474997ADec 12, 1995
Methods and compositions of (2R,4S) itraconazole for treating fungal yeast and dermatophyte infections
SEPRACOR INC66 citations95
US6066654AMay 23, 2000
Methods for treating disorders associated with the central nervous system using optically pure (-) cisapride
SEPRACOR INC16 citations93
US5955477ASep 21, 1999
Methods for treating gastrointestinal motility dysfunction using optically pure (--) cisapride
SEPRACOR INC17 citations93
US5955478ASep 21, 1999
Methods for treating gastrointestinal motility dysfunction using optically pure (+) cisapride
SEPRACOR INC19 citations93
US5888535AMar 30, 1999
Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
SEPRACOR INC28 citations92
US5698558ADec 16, 1997
Methods for treating allergic disorders using optically pure (-) cetirizine
SEPRACOR INC38 citations92
US5627183AMay 6, 1997
Methods for treating urticaria using optically pure (+) cetirizine
SEPRACOR INC27 citations92
US5561151AOct 1, 1996
Antipyretic and analgesic methods of using optically pure R-etodolac
SEPRACOR INC28 citations92
US6040307AMar 21, 2000
Methods ad compositions of (-) ketoconazole for treating fungal yeast and dermatophyte infections
SEPRACOR INC34 citations87
US5629329AMay 13, 1997
Methods for treating disorders associated with the central nervous system using opticallly pure (+) cisapride
SEPRACOR INC15 citations82
US5629328AMay 13, 1997
Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (+) cisapride
SEPRACOR INC14 citations82
US5618828AApr 8, 1997
Methods for treating gastro-esophageal reflux disease and emesis with optically pure (-) cisapride
SEPRACOR INC16 citations82
US6953808B2Oct 11, 2005
Method for treating gastric disorders using optically pure (−) pantoprazole
SEPRACOR INC10 citations74
US5629337AMay 13, 1997
Methods for treating asthma using optically pure (-)-zileuton
SEPRACOR INC12 citations74
US5508279AApr 16, 1996
Methods and compositions of (+) doxazosin for the treatment of benign prostatic hyperplasia
SEPRACOR INC10 citations74
US6069154AMay 30, 2000
Methods for treating gastro-esophageal reflux disease using optically pure (+) cisapride
SEPRACOR INC2 citations63
US5510352AApr 23, 1996
Methods of using (+) doxazosin for the treatment of hypertension
SEPRACOR INC2 citations63
US5492933AFeb 20, 1996
Methods and compositions for treating urinary incontinence and other disorders using optically pure R-terodiline and hydroxylated derivatives thereof
SEPRACOR INC5 citations63
SEARLE & CO
7 patentsUS5215992AJun 1, 1993
Ethanobicyclic amine derivatives for CNS disorders
SEARLE & CO39 citations92
US5098916AMar 24, 1992
Propanobicyclic amine derivatives for cns disorders
SEARLE & CO42 citations92
US5089506AFeb 18, 1992
Ethanobicyclic amine derivatives for cns disorders
SEARLE & CO40 citations92
US5055468AOct 8, 1991
Use of bridged tricyclic amine derivatives as anti-ischemic agents
SEARLE & CO30 citations92
US5229413AJul 20, 1993
Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders
SEARLE & CO11 citations72
US5130330AJul 14, 1992
Nitrogen-containing cyclohetero cycloalkylaminoaryl derivatives for cns disorders
SEARLE & CO11 citations72
US5401755AMar 28, 1995
N-(1-thienylcycloalkyl)alkenylamines for treatment of neurotoxic injury
SEARLE & CO3 citations60